Perspective Therapeutics (FRA:AAJ0) Net Margin %: 0.00% (As of Mar. 2026)


FRA:AAJ0 Perspective Therapeutics Inc FRA:AAJ0
31 GF Score
Price €2.56
! 1 Warning Sign
View Full Analysis

What is Perspective Therapeutics Net Margin %?

Perspective Therapeutics FRA:AAJ0 +3.72% 31 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:AAJ0 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 817 Medical Devices & Instruments companies, Perspective Therapeutics ranks worse than 122398.9% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Perspective Therapeutics's Net Income for the three months ended in Mar. 2026 was €-22.65 Mil. Perspective Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Perspective Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Perspective Therapeutics's Net Margin % or its related term are showing as below:


FRA:AAJ0's Net Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.07
* Ranked among companies with meaningful Net Margin % only.

Perspective Therapeutics  (FRA:AAJ0) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Perspective Therapeutics Net Margin % Related Terms


Perspective Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Perspective Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics Net Margin % Chart

Perspective Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.69 -67.36 0.00 0.00 0.00

Perspective Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:AAJ0 vs LAB, KIDS, PACB: Net Margin % Comparison

For the Medical Devices subindustry, Perspective Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perspective Therapeutics Net Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's Net Margin % falls into.


FRA:AAJ0
31GF Score
Perspective Therapeutics Inc FRA:AAJ0
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perspective Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Perspective Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-88.065/0
= %

Perspective Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-22.653/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Perspective Therapeutics (FRA:AAJ0) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Perspective Therapeutics and its competitors. According to the industry distribution chart, Perspective Therapeutics ranks #999999 out of 817 companies in the Medical Devices & Instruments industry.
Is Perspective Therapeutics' Net Margin % too high?
Perspective Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Perspective Therapeutics ranks #999999 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Perspective Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Net Margin % compare to LAB and KIDS?
According to the Medical Devices & Instruments industry distribution chart, Perspective Therapeutics ranks #999999 out of 817 companies for Net Margin %. This places Perspective Therapeutics in the lower half of its industry. The industry median Net Margin % is 2.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Perspective Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perspective Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (FRA:AAJ0) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Perspective Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Perspective Therapeutics (FRA:AAJ0), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Perspective Therapeutics Business Description

Other Exchanges CATX:USA
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
31GF Score

Get the complete analysis for FRA:AAJ0

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.56
Price